Chinook Therapeutics to Present at the Guggenheim Healthcare Talks | Genomic Medicines and Rare Disease Days
Chinook Therapeutics, a biopharmaceutical company focused on kidney disease treatments, will participate in the Guggenheim Healthcare Talks on April 4, 2023, at 10:45 am ET. This event includes a virtual fireside chat and 1x1 meetings with investors. Interested parties can access the live webcast and archived recordings through the company's website for 90 days. Chinook's lead program is atrasentan, currently in phase 3 trials for IgA nephropathy. Other candidates include BION-1301 and CHK-336, targeting rare kidney disorders. The company aims to leverage genetic insights to advance precision medicine for chronic kidney diseases.
- None.
- None.
SEATTLE, March 28, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to participate in a virtual fireside chat at the Guggenheim Healthcare Talks | Genomic Medicines and Rare Disease Days on Tuesday, April 4th at 10:45 am ET, as well as 1x1 meetings with investors.
To access the live webcast and subsequent archived recording of this and other company presentations, please visit the Investors section of Chinook’s website. The archived webcast will remain available for replay on Chinook’s website for 90 days.
About Chinook Therapeutics, Inc.
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for kidney diseases. Chinook’s product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. Chinook’s lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and proteinuric glomerular diseases. BION-1301, an anti-APRIL monoclonal antibody, is being evaluated in a phase 1/2 trial for IgA nephropathy. CHK-336, an oral small molecule LDHA inhibitor for the treatment of hyperoxalurias, is being evaluated in a phase 1 clinical trial in healthy volunteers. In addition, Chinook’s research and discovery efforts are focused on building a pipeline of precision medicines for rare, severe chronic kidney diseases with defined genetic and molecular drivers. Chinook is leveraging insights from kidney single cell RNA sequencing and large CKD patient cohorts that have been comprehensively panomically phenotyped, with retained biosamples and prospective clinical follow-up, to discover and develop therapeutic candidates with mechanisms of action targeted against key kidney disease pathways. To learn more, visit www.chinooktx.com.
FAQ
When is Chinook Therapeutics participating in the Guggenheim Healthcare Talks?
Where can I watch the Chinook Therapeutics webcast?
What is the lead program of Chinook Therapeutics?
What other drug candidates is Chinook Therapeutics developing?
How long will the archived webcast be available for replay?
